Dolby Laboratories, Inc.
For the period ended Jun 27, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 27, 2025 · Filed Jul 31, 2025
DLB$64.67-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveIncome/(Loss) | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance as of March 28, 2025 | $95 | $— | $2,601,552 | $(27,978) | $2,573,669 | $9,350 | $2,583,019 |
| Net income | — | — | 46,071 | — | 46,071 | 471 | 46,542 |
| Other comprehensive income, net of tax | — | — | — | 14,454 | 14,454 | 165 | 14,619 |
| Distributions to noncontrolling interest | — | — | — | — | — | (468) | (468) |
| Stock-based compensation expense | — | 30,728 | — | — | 30,728 | — | 30,728 |
| Capitalized stock-based compensation expense | — | 82 | — | — | 82 | — | 82 |
| Repurchase of common stock | — | (42,164) | 2,173 | — | (39,991) | — | (39,991) |
| Cash dividends declared and paid on common stock | — | — | (31,633) | — | (31,633) | — | (31,633) |
| Common stock issued under employee stock plans | — | 12,557 | — | — | 12,557 | — | 12,557 |
| Tax withholdings on vesting of restricted stock | (1) | (1,203) | — | — | (1,204) | — | (1,204) |
| Balance as of June 27, 2025 | $94 | $— | $2,618,163 | $(13,524) | $2,604,733 | $9,518 | $2,614,251 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveIncome/(Loss) | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance as of September 27, 2024 | $94 | $— | $2,496,255 | $(19,187) | $2,477,162 | $9,731 | $2,486,893 |
| Net income | — | — | 205,686 | — | 205,686 | 1,152 | 206,838 |
| Other comprehensive income, net of tax | — | — | — | 5,663 | 5,663 | 84 | 5,747 |
| Distributions to noncontrolling interest | — | — | — | — | — | (1,449) | (1,449) |
| Stock-based compensation expense | — | 97,462 | — | — | 97,462 | — | 97,462 |
| Capitalized stock-based compensation expense | — | 233 | — | — | 233 | — | 233 |
| Repurchase of common stock | (1) | (101,238) | 11,249 | — | (89,990) | — | (89,990) |
| Cash dividends declared and paid on common stock | — | — | (95,010) | — | (95,010) | — | (95,010) |
| Common stock issued under employee stock plans | 2 | 38,679 | — | — | 38,681 | — | 38,681 |
| Tax withholdings on vesting of restricted stock | (1) | (35,136) | (17) | — | (35,154) | — | (35,154) |
| Balance as of June 27, 2025 | $94 | $— | $2,618,163 | $(13,524) | $2,604,733 | $9,518 | $2,614,251 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | Accumulated Other Comprehensive Loss | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance as of March 29, 2024 | $94 | $— | $2,449,876 | $(29,068) | $2,420,902 | $16,785 | $2,437,687 |
| Net income | — | — | 38,444 | — | 38,444 | 1,211 | 39,655 |
| Other comprehensive loss, net of tax | — | — | — | (1,104) | (1,104) | 46 | (1,058) |
| Distributions to noncontrolling interest | — | — | — | — | — | (3,448) | (3,448) |
| Stock-based compensation expense | — | 29,337 | — | — | 29,337 | — | 29,337 |
| Capitalized stock-based compensation expense | — | 206 | — | — | 206 | — | 206 |
| Repurchase of common stock | (1) | (38,310) | 3,311 | — | (35,000) | — | (35,000) |
| Cash dividends declared and paid on common stock | — | — | (28,703) | — | (28,703) | — | (28,703) |
| Common stock issued under employee stock plans | 1 | 10,141 | — | — | 10,142 | — | 10,142 |
| Tax withholdings on vesting of restricted stock | — | (1,374) | — | — | (1,374) | — | (1,374) |
| Equity issued in connection with business combination | — | — | — | — | — | (12) | (12) |
| Balance as of June 28, 2024 | $94 | $— | $2,462,928 | $(30,172) | $2,432,850 | $14,582 | $2,447,432 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | Accumulated Other Comprehensive Income/(Loss) | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance as of September 29, 2023 | $94 | $— | $2,391,990 | $(36,984) | $2,355,100 | $17,084 | $2,372,184 |
| Net income | — | — | 203,255 | — | 203,255 | 2,195 | 205,450 |
| Other comprehensive income, net of tax | — | — | — | 6,812 | 6,812 | 125 | 6,937 |
| Distributions to noncontrolling interest | — | — | — | — | — | (4,495) | (4,495) |
| Stock-based compensation expense | — | 90,146 | — | — | 90,146 | — | 90,146 |
| Capitalized stock-based compensation expense | — | 411 | — | — | 411 | — | 411 |
| Repurchase of common stock | (2) | (92,974) | (47,023) | — | (139,999) | — | (139,999) |
| Cash dividends declared and paid on common stock | — | — | (85,971) | — | (85,971) | — | (85,971) |
| Common stock issued under employee stock plans | 2 | 39,485 | — | — | 39,487 | — | 39,487 |
| Tax withholdings on vesting of restricted stock | — | (37,428) | — | — | (37,428) | — | (37,428) |
| Deconsolidation of subsidiary | — | — | 677 | — | 677 | (677) | — |
| Equity issued in connection with business combination | — | 360 | — | — | 360 | 350 | 710 |
| Balance as of June 28, 2024 | $94 | $— | $2,462,928 | $(30,172) | $2,432,850 | $14,582 | $2,447,432 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.